TG Therapeutics | TGTX - Operating Profit


TG Therapeutics reported $34.8M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Alaunos Therapeutics USD -1.01M 175K Mar/2026
Amgen USD 3.83B 130M Mar/2026
Ardelyx USD 5.1M 431K Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
Corcept Therapeutics USD -49.6M 54.09M Mar/2026
Curis USD -7.88M 4.63M Dec/2025
Gilead Sciences USD 2.68B 284M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Novavax USD 20.94M 100.32M Dec/2025
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
TG Therapeutics USD 34.8M 15.7M Mar/2026
Verastem USD -41.48M 23.2M Dec/2025
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026